These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 23030324)

  • 21. The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis.
    Deng HP; Chai JK
    Int Immunopharmacol; 2009 Oct; 9(11):1251-9. PubMed ID: 19647101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the understanding of clinical manifestations and therapy of severe sepsis: an update for critical care nurses.
    Ely EW; Kleinpell RM; Goyette RE
    Am J Crit Care; 2003 Mar; 12(2):120-33; quiz 134-5. PubMed ID: 12625170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure.
    Eisele B; Lamy M
    Semin Thromb Hemost; 1998; 24(1):71-80. PubMed ID: 9515782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucose control in the intensive care unit.
    Fahy BG; Sheehy AM; Coursin DB
    Crit Care Med; 2009 May; 37(5):1769-76. PubMed ID: 19325461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent evolution of renal replacement therapy in the critically ill patient.
    Ronco C
    Crit Care; 2006 Feb; 10(1):123. PubMed ID: 16542480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical illness myopathy: sepsis-mediated failure of the peripheral nervous system.
    Friedrich O
    Eur J Anaesthesiol Suppl; 2008; 42():73-82. PubMed ID: 18289421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory therapy for sepsis: an update.
    Christaki E; Anyfanti P; Opal SM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1013-33. PubMed ID: 22029521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulation in sepsis: state of the art and future perspective.
    Antonopoulou A; Giamarellos-Bourboulis EJ
    Immunotherapy; 2011 Jan; 3(1):117-28. PubMed ID: 21174562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis.
    Cao C; Yu M; Chai Y
    Cell Death Dis; 2019 Oct; 10(10):782. PubMed ID: 31611560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting caspases in sepsis.
    Aziz M; Jacob A; Wang P
    Cell Death Dis; 2014 Nov; 5(11):e1526. PubMed ID: 25412304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial design for unmet clinical needs: a spotlight on sepsis.
    Vincent JL; Sakr Y
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):893-900. PubMed ID: 31295413
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathogenetic aspects of sepsis and possible targets for adjunctive therapy.
    Rigato O; Silva E; Kallas EG; Brunialti MK; Martins PS; Salomao R
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 May; 1(1):13-30. PubMed ID: 12476779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACUTE DIALYSIS QUALITY INITIATIVE (ADQI) XIV SEPSIS PHENOTYPES AND TARGETS FOR BLOOD PURIFICATION IN SEPSIS: THE BOGOTÁ CONSENSUS.
    Kellum JA; Gómez H; Gómez A; Murray P; Ronco C;
    Shock; 2016 Mar; 45(3):242-8. PubMed ID: 26871663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.
    Hall TC; Bilku DK; Al-Leswas D; Horst C; Dennison AR
    Ir J Med Sci; 2012 Mar; 181(1):1-6. PubMed ID: 22065211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms of sepsis.
    Russell JA; Boyd J; Nakada T; Thair S; Walley KR
    Contrib Microbiol; 2011; 17():48-85. PubMed ID: 21659747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advancements of nanomaterial-based therapeutic strategies toward sepsis: bacterial eradication, anti-inflammation, and immunomodulation.
    Zhao Y; Pu M; Zhang J; Wang Y; Yan X; Yu L; He Z
    Nanoscale; 2021 Jun; 13(24):10726-10747. PubMed ID: 34165483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Signaling pathways and intervention therapies in sepsis.
    Zhang YY; Ning BT
    Signal Transduct Target Ther; 2021 Nov; 6(1):407. PubMed ID: 34824200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis-oriented targets for adjunctive therapy.
    Rigato O; Silva E; Salomao R
    Endocr Metab Immune Disord Drug Targets; 2006 Jun; 6(2):193-200. PubMed ID: 16787294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.